Literature DB >> 1382543

Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells.

H F Barker1, M S Hamilton, J Ball, M Drew, I M Franklin.   

Abstract

Normal and malignant plasma cells were investigated for the expression of seven cellular adhesion molecules by immunofluorescence microscopy. The antigens investigated were CD2 and its ligand, LFA-3 (CD58). LFA-1 alpha (CD11a) and LFA-1 beta (CD18) and their ligand ICAM-1 (CD54), H-CAM (lymphocyte homing receptor; CD44) and N-CAM (CD56). Marrow from 18 patients with myeloma, two with plasma cell leukaemia (PCL), four with monoclonal gammopathy of uncertain significance (MGUS) and 10 normal allogeneic bone marrow donors was studied. All plasma cells from normals and multiple myeloma patients were negative for CD2, CD11a and CD18. All normal and myeloma marrow plasma cells were positive for ICAM-1. 16/18 myeloma cases tested, and all other samples (normal, MGUS and PCL), contained plasma cells positive for H-CAM. Only one normal, but 12/16 myelomas tested were positive for N-CAM (P less than 0.02). One of four MGUS cases was moderately positive and one other weakly positive for N-CAM. Both PCLs were N-CAM negative. 12/18 myelomas were positive for LFA-3, but only two normals (P less than 0.05). All MGUS cases were negative for LFA-3, as was one PCL, the other being weakly positive. Three cases were negative for both adhesion molecules, three cases expressed only N-CAM or LFA-3 and 10 cases expressed both. LFA-3 and N-CAM are expressed significantly in myeloma rather than normal plasma cells. Cases of MGUS may express N-CAM but not, in this small series, LFA-3. Plasma cells in the peripheral blood (PCL) and plasma cell lines express little or no LFA-3 or N-CAM.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382543     DOI: 10.1111/j.1365-2141.1992.tb08236.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.

Authors:  M Zandecki; T Facon; F Bernardi; V Izydorczyk; L Dupond; M François; R Reade; T Iaru; F Bauters; A Cosson
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

Review 2.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

3.  CD31 (JC70) expression in plasma cells: an immunohistochemical analysis of reactive and neoplastic plasma cells.

Authors:  D Govender; P Harilal; M Dada; R Chetty
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

Review 4.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

5.  Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

Authors:  M Ocqueteau; A Orfao; J Almeida; J Bladé; M González; R García-Sanz; C López-Berges; M J Moro; J Hernández; L Escribano; D Caballero; M Rozman; J F San Miguel
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

6.  A novel flow cytometric assay for the quantification of adhesion of subsets within a heterogeneous cell population; analysis of lymphocyte function-associated antigen-1 (LFA-1)-mediated binding of bone marrow-derived primary tumour cells of patients with multiple myeloma.

Authors:  E J Ahsmann; R J Benschop; T D de Gruyl; J A Faber; H M Lokhorst; A C Bloem
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

Review 7.  Homing behaviour of the malignant cell clone in multiple myeloma.

Authors:  I Van Riet; K Vanderkerken; C de Greef; B Van Camp
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

Review 8.  Plasma cell leukemia producing monoclonal immunoglobulin E.

Authors:  Yuzuru Takemura; Masanobu Ikeda; Kahori Kobayashi; Yuji Nakazawa; Yuichi Mori; Toshimi Mitsuishi; Hiroki Ishigame; Fumiko Kameko; Kiyotaka Fujita; Ryo Ichinohasama
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

9.  Understanding the multiple biological aspects leading to myeloma.

Authors:  Eileen M Boyle; Faith E Davies; Xavier Leleu; Gareth J Morgan
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

10.  Expression of adhesion molecules on myeloma cells.

Authors:  T Tatsumi; C Shimazaki; H Goto; S Araki; Y Sudo; N Yamagata; E Ashihara; T Inaba; N Fujita; M Nakagawa
Journal:  Jpn J Cancer Res       Date:  1996-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.